SUO 2016: Addressing patient expectations - Session Highlights

San Antonio, Texas USA ( Behfar Ehdaie, Memorial Sloan Kettering Cancer Center, reviewed issues regarding discussions with patients regarding outcomes with partial gland ablation.

Biopsy pathology is associated with recurrent disease. Focal ablation is not cure and needs to be carefully discussed with patients. Retreatment is not uncommon after partial gland ablation in addition to possibly increased costs associated with these treatments versus more definitive measures. Partial gland ablation is safe and has favorable functional outcomes, however, continence and potency may not be the only meaningful quality of life endpoints. Patient orgasm, ejaculatory dysfunction and painful intercourse in addition to other factors within urinary sexual domains measured with standardized instruments need to be taken into careful consideration.

Presented by: Behfar Ehdaie, Memorial Sloan Kettering Cancer Center

Written By: Stephen B. Williams, MD and Ashish M. Kamat

17th Annual Meeting of the Society of Urologic Oncology - November 30 -December 2, 2016 – San Antonio, Texas USA

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.